Skip to main content
NVCR logo
NVCR
(NASDAQ)
NovoCure Limited
$17.75-- (--)
Loading... - Market loading

NovoCure (NVCR) Company Profile

Complete business overview, executive team, trading details, and corporate information.

NovoCure Limited
NVCRNasdaq Stock Market

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Company Information

CEOFrank Leonard
Founded2000
Employees1,605
CountryJersey
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Address
Neuhofstrasse 21 Baar, 6340 Switzerland

Corporate Identifiers

CUSIPG6674U108
ISINJE00BYSS4X48
SIC3845

Leadership Team & Key Executives

Frank Leonard
Chief Executive Officer
Christoph Brackmann
Chief Financial Officer
Mukund Paravasthu
Chief Operating Officer
Adam Daney
Head of Investor Relations